Haloperidol

Generic Name
Haloperidol
Brand Names
Haldol
Drug Type
Small Molecule
Chemical Formula
C21H23ClFNO2
CAS Number
52-86-8
Unique Ingredient Identifier
J6292F8L3D
Background

Haloperidol is a high potency first-generation (typical) antipsychotic and one of the most frequently used antipsychotic medications used worldwide. While haloperidol has demonstrated pharmacologic activity at a number of receptors in the brain, it exerts its antipsychotic effect through its strong antagonism of the dopamine receptor (mainly D2), particularl...

Indication

Haloperidol is indicated for a number of conditions including for the treatment of schizophrenia, for the manifestations of psychotic disorders, for the control of tics and vocal utterances of Tourette’s Disorder in children and adults, for treatment of severe behavior problems in children of combative, explosive hyperexcitability (which cannot be accounted ...

Associated Conditions
Aggression, Delirium, Gilles de la Tourette's Syndrome, Huntington's Disease (HD), Nausea and vomiting, Obsessive Compulsive Disorder (OCD), Psychosis, Schizophrenia, Severe Disruptive Behaviour Disorders, Severe Hyperactivity
Associated Therapies
-

Comparative Efficacy of Dexamethasone - Ondansetron Versus Dexamethasone - Haloperidol in Reducing PONV

First Posted Date
2024-05-24
Last Posted Date
2024-05-24
Lead Sponsor
Universitas Padjadjaran
Target Recruit Count
38
Registration Number
NCT06428084
Locations
🇮🇩

Hasan Sadikin General Hospital, Bandung, West Java, Indonesia

Haloperidol for Pain Control in Patients With Acute Musculoskeletal Back Pain in the Emergency Department

First Posted Date
2024-05-02
Last Posted Date
2024-07-10
Lead Sponsor
Western Michigan University School of Medicine
Target Recruit Count
75
Registration Number
NCT06395428
Locations
🇺🇸

Bronson Methodist Hospital, Kalamazoo, Michigan, United States

Intranasal Dexmedetomidine vs. Standard of Care for Emergency Department (ED) Procedural Sedation in the Older Adult

First Posted Date
2024-04-17
Last Posted Date
2024-04-22
Lead Sponsor
State University of New York - Upstate Medical University
Target Recruit Count
60
Registration Number
NCT06370442

A Study of Olanzapine in Patients With Acute Agitation

Phase 3
Not yet recruiting
Conditions
Interventions
First Posted Date
2023-04-07
Last Posted Date
2023-04-07
Lead Sponsor
Qilu Pharmaceutical Co., Ltd.
Target Recruit Count
318
Registration Number
NCT05803642

Quetiapine Versus Haloperidol in the Management of Hyperactive Delirium

Phase 3
Completed
Conditions
Interventions
First Posted Date
2023-01-19
Last Posted Date
2023-08-30
Lead Sponsor
Alexandria University
Target Recruit Count
100
Registration Number
NCT05690698
Locations
🇪🇬

Faculty of Medicine, Alexandria University Hospitals, Alexandria, Egypt

Managing Agitated Delirium with Neuroleptics and Anti-Epileptics As a Neuroleptic Sparing Strategy

First Posted Date
2022-06-24
Last Posted Date
2024-12-04
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
30
Registration Number
NCT05431595
Locations
🇺🇸

MD Anderson Cancer Center, Houston, Texas, United States

Haloperidol, Droperidol, Ondansetron in Cannabis Hyperemesis

First Posted Date
2021-10-04
Last Posted Date
2023-11-28
Lead Sponsor
Spectrum Health - Lakeland
Target Recruit Count
38
Registration Number
NCT05065567
Locations
🇺🇸

Lakeland Regional Healthcare, Saint Joseph, Michigan, United States

Haloperidol for the Treatment of Nausea and Vomiting in the ED

First Posted Date
2021-02-21
Last Posted Date
2023-06-01
Lead Sponsor
Western Michigan University School of Medicine
Target Recruit Count
60
Registration Number
NCT04764344
Locations
🇺🇸

Bronson Methodist Hospital, Kalamazoo, Michigan, United States

Meth-OD: A Study of IXT-m200 in Patients With Toxicity From Methamphetamine Overdose

First Posted Date
2021-01-20
Last Posted Date
2023-11-18
Lead Sponsor
InterveXion Therapeutics, LLC
Target Recruit Count
20
Registration Number
NCT04715230
Locations
🇺🇸

University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States

🇺🇸

Sacred Heart Medical Center, Spokane, Washington, United States

🇺🇸

University of New Mexico Hospital, Albuquerque, New Mexico, United States

and more 1 locations

Treatment Strategies in CHS

Phase 4
Completed
Conditions
Interventions
First Posted Date
2019-11-25
Last Posted Date
2022-08-10
Lead Sponsor
University of Calgary
Target Recruit Count
4
Registration Number
NCT04176055
Locations
🇨🇦

University of Calgary, Calgary, Alberta, Canada

© Copyright 2024. All Rights Reserved by MedPath